-+ 0.00%
-+ 0.00%
-+ 0.00%

NuCana's NUC-7738 Enhances Carfilzomib Activity in Preclinical Multiple Myeloma Study

PUBT·11/20/2026 13:00:51
Listen to the news
NuCana's NUC-7738 Enhances Carfilzomib Activity in Preclinical Multiple Myeloma Study
  • NuCana presented preclinical findings Nov. 20, 2026, showing NUC-7738 enhanced carfilzomib's anti-cancer activity in multiple myeloma cell lines.
  • The laboratory results support further evaluation of the combination in multiple myeloma, with broader screening suggesting potential in other cancers.
  • Final Phase 2 results for NUC-7738 with pembrolizumab in PD-1 inhibitor-resistant metastatic melanoma will be presented Dec. 14-16, 2026, in London.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200800OMX_____CNEWS_EN_GNW9880801_en) on November 20, 2026, and is solely responsible for the information contained therein.